ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1264 • ACR Convergence 2025

    Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt

    Daniel Garcia1, Vanessa Madrigal2, Noelia Hernandez3, Alisha Akinsete4, Iris Navarro-Millan5, Ileana Vazquez Otero6, Ariana Gonzalez Melendez7, Sarah Young8 and Monika Safford2, 1Weill Cornell, Brooklyn, NY, 2Weill Cornell Medicine, New York, 3Weill Cornell Medicine, New York, NY, 4Weill Cornell Medical Center, New York, NY, 5Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 6Clinica Reuviva, San Juan, PR, 7Ponce Health Sciences, San Juan, PR, 8Weill Cornell Medicine, Johnson City, NY

    Background/Purpose: Approximately 1.3 million Americans have rheumatoid arthritis (RA)1. Up to 83% of people with chronic pain, the hallmark symptom of RA also experience anxiety…
  • Abstract Number: 1094 • ACR Convergence 2025

    Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects

    Carmen Lasa Teja1, Juan José Fernández-Cabero2, Alejandra Comins-Boo3, David San Segundo3, Virginia Portilla González4, Montserrat Santos-Gomez5, José Luis Martín-Varillas6, Marcos López-Hoyos3 and Ricardo Blanco7, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 2Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, 3Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, 5Division of Immunology, Hospital Sierrallana. Santander , Spain, Santander, Spain, 6Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 7Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Janus kinase inhibitors (JAKi) are effective in rheumatoid arthritis (RA); however, concerns regarding safety, particularly the risk of infections and malignancies, have been raised.…
  • Abstract Number: 1017 • ACR Convergence 2025

    Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network

    James Wei1, Shiow-Ing Wang2 and Ying-Li Lin2, 1Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), 2Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster…
  • Abstract Number: 0919 • ACR Convergence 2025

    Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns

    Stefanie Kurth1, Andre Tiaden1, Edveena Hanser1, Simone Häner1, Stavros Giaglis1, Florian Geier1, Dominik Burri1, Katarzyna Buczak1, Ute Heider2, Stefan Wild2, Yves Acklin1, Christian Egloff1 and Diego Kyburz3, 1University of Basel, Basel, Switzerland, 2Miltenyi Biotec, Bergisch-Gladbach, Germany, 3University Hospital Basel, Basel, Switzerland

    Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
  • Abstract Number: 0832 • ACR Convergence 2025

    Elevated serum peptidylarginine deiminase 4 (PAD4) levels in anti-CCP antibody positive at-risk individuals with arthralgia who progress to rheumatoid arthritis.

    Sana Sharrack1, Xia Yu2, Arun Jayaraman3, Laurence Duquenne4, Andrea Di Matteo5, Kate Harnden5, Lucy Thornton5, Helen Jayne-Sugden5, Jacqueline Nam6, Adam Smith5, Mia Collins7, Rachel Sparks3, Fanyi Jiang8, Kyriakos Konstantinidis9, Jessica Neisen10, Greet De Baets10, David Close11, Chris chamberlain10, Adam Platt12, Paul Emery13, Josie Meade2 and Kulveer Mankia13, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Sheffield, United Kingdom, 2Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, 3AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gaithersburg, Maryland, United States of America, Gaithersburg, Maryland, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, United Kingdom, Leeds, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, 6Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, 7AstraZeneca, Gothenburg, Sweden, 8AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gothenburg, Sweden, Gothenburg, Sweden, 9AstraZeneca, R&I Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D,, Cambridge, United Kingdom, Cambridge, United Kingdom, 10AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Cambridge, United Kingdom, 11AstraZeneca, Royston, United Kingdom, 12AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Melbourn, Royston,, United Kingdom, 13University of Leeds, Leeds, England, United Kingdom

    Background/Purpose: Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies are one of the strongest risk factors for the development of rheumatoid arthritis (RA). Anti-CCP antibodies are generated against…
  • Abstract Number: 0532 • ACR Convergence 2025

    Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis

    Antonio Tonutti1, Saverio D'Amico2, Pierandrea Morandini2, Cosimo Faeti2, Elisa Barone1, Nicoletta Luciano1, Victor Savevski2 and Carlo Selmi3, 1Humanitas University, Pieve Emanuele, Italy, 2IRCCS Humanitas Research Hospital, Rozzano, Italy, 3Humanitas University, Milan, Italy

    Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…
  • Abstract Number: 0488 • ACR Convergence 2025

    Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

    Jérôme Avouac1, Neil Betteridge2, Karen Bevers3, Gerd Burmester4, Roberto Caporali5, Ouafia Bouzid6, Thomas Debray6, Carole Van der Donckt6, James Galloway7, Susana Romero-Yuste8 and Patrick Verschueren9, 1Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 2Neil Betteridge Associates, London, United Kingdom, 3Sint Maartenskliniek, Nijmegen, Netherlands, 4Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 6Alfasigma S.p.A., Bologna, Italy, 7King's College London, London, United Kingdom, 8University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
  • Abstract Number: 0472 • ACR Convergence 2025

    Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness

    Sung Eun Kim1, Hye Lim Kang1, Min Jung Kim2, Hyung-Sik Kim3 and Kichul Shin4, 1Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 2Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, 3Department of Oral Biochemistry, Pusan National University School of Dentistry, Yangsan, Republic of Korea, 4Seoul National University, Seoul, South Korea

    Background/Purpose: Studies have shown that mesenchymal stem cell (MSC) infusion ameliorates arthritis in animal models. However, the first-pass effect in the lung has directed attention…
  • Abstract Number: 0456 • ACR Convergence 2025

    Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.

    Nisha Sapkota1, Samuel Sule-saa1, Yubraj Aryal2, Mark Ntow3, Karuna Bista4, Parvathy Rajeev3, jemima Alemonai3, Esther Duodu5, Brijesh Ghimire3, Pyae Hein3, Jeffrey Sackey6, Muhanned Towfig3, Robert Lamptey3, Temesgen Gobena7, Daniel Pinkrah7 and Mona Pervil Ulysse8, 1Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, 2Geisinger Medical Center, Danville, PA, 3Interfaith Medical Center, One Broolyn Health, Brooklyn, 4Montefiore New Rochelle Hospital, New Rochelle, NY, 5Broodale Hospital Medical Center, One Broolyn Health, Brooklyn, 6Interfaith Medical Center,One Broolyn Health, Brooklyn, 7Interfaith Medical Center, Brooklyn, NY, 8Interfaith Medical Center, One Brooklyn Health, Brooklyn

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with systemic inflammation and increased cardiovascular risk, particularly heart failure (HF). Patients with RA and…
  • Abstract Number: 0438 • ACR Convergence 2025

    Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis

    Bindee Kuriya1, Susan J. Bartlett2, Marie-France Valois3, Janet Pope4, Carter Thorne5, Carol Hitchon6, Hugues Allard-Chamard7, Glen Hazlewood8, Gilles Boire9, Louis Bessette10 and Vivian Bykerk11, 1Mount Sinai Health, Toronto, Canada, 2McGill University, Beaconsfield, QC, Canada, 3McGill University, Pointe-Claire, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Centre of Arthritis Excellence, Newmarket, ON, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Université de Sherbrooke, Sherbrooke, Canada, 8University of Calgary, Calgary, AB, Canada, 9Retired, Sherbrooke, QC, Canada, 10Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, 11Hospital for Special Surgery, New York, NY

    Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
  • Abstract Number: 0348 • ACR Convergence 2025

    Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients

    Karla Miller1, Amani Jridi2 and Tina Basak3, 1University of Utah School of Medicine, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Utah Department of Radiology, Salt Lake City, UT

    Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk of having generalized osteoporosis of the axial and appendicular skeleton assessed by dual-energy x-ray absorptiometry (DXA)…
  • Abstract Number: 0180 • ACR Convergence 2025

    Digital Transformation in IMID Care: Results from the Implementation of IMIDOC

    JOSE INIESTA-CHAMORRO1, Marta Novella-Navarro2, Diego Benavent3, HELENA BORREL-PAÑOS4, Xabier Michelena Vegas5, Javier Bachiller6, Verónica García García7, ESTHER ESPARTAL4, LETICIA LOJO-OLIVEIRA8, Enrique Calvo-Aranda9, José Rodríguez gago10, Gema Bonilla11, Irene Monjo Henry2, Victoria Navarro-Compan12, Jaime Arroyo10, Eugenio de Miguel2, Mariana Díaz-Almirón13, cARMEN ALEGRE10, ENRIQUE J GÓMEZ14 and Chamaida Plasencia-Rodríguez2, 11Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, 2Hospital Universitario La Paz, Madrid, Spain, 3Hospital Universitari de Bellvitge, Madrid, Spain, 44HOSPITAL UNIVERSITARIO VALL D´HEBRON, RHEUMATOLOGY, BARCELONA, Spain,, BARCELONA, 5Hospital Universitari Vall Hebron, Barcelona, Spain, 6Hospital Ramon y Cajal, Madrid, Madrid, Spain, 7Ramón y Cajal University Hospital, MADRID, Spain, 8Hospital Universitario Infanta Leonor, Madrid, Spain, 9Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, madrid, 10Hospital Universitario La Paz, MADRID, 11Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, 12Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 13LIMA, Advanced Medical Informatics Lab, La Paz Research Institute, IdiPAZ, Madrid, Spain, 141Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, Spain,, MADRID

    Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…
  • Abstract Number: 0092 • ACR Convergence 2025

    SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging

    Mojtaba S. Fazli1, Mariani Diaz Deluna2, Suzanne Tamang2 and Robert Fairchild2, 1Stanford University, San Francisco, CA, 2Stanford University, Stanford, CA

    Background/Purpose: Rheumatology musculoskeletal ultrasound (MSKUS) is a powerful technique to identify and differentiate arthritidies joint pathology, yet MSKUS is highly dependent on user experience. Techniques…
  • Abstract Number: 0074 • ACR Convergence 2025

    Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

    Sophie Hopkin1, Kathryn Malpas1, David Kallenberg1, Jacqueline O'Neill1, Geofrey Odede1, Kerry Tyson1, Sue Cross1, Tatiana SOKOLOVA2, Bernard Lauwerys3, Baran Ufuktepe4, Patrick Durez5, Susanna Bidgood1 and David Humphreys1, 1UCB Pharma, Slough, England, United Kingdom, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 3Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, 4UCB Pharma Istanbul, Turkey, istanbul, Turkey, 5Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…
  • Abstract Number: 0053 • ACR Convergence 2025

    The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model

    Jérôme Avouac1, manon lesturgie2, Virginie Gonzalez3, Sujeeba Arulananthan2, Anne Cauvet3, Francoise Tilotta4 and Yannick Allanore5, 1Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 2INSERM U1016, Paris, France, 3INSERMU1016, Paris, France, 4Université Paris Cité, Montrouge, France, 5Université Paris Cité, Paris, France

    Background/Purpose: CCN1, a matricellular protein with angiogenic and immunomodulatory properties, is overexpressed in endothelial and synovial tissues of rheumatoid arthritis (RA) patients. Previous findings demonstrated…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology